Bastien Gerby

**Name:** GERBY Bastien ; **Date of birth:** 1982/10/15 ; **Nationality:** French **EDUCATION** 2010 - Ph.D in Blood Cell Biology - University Denis-Diderot, Paris, France. 2008 - Degree Level I - Animal experimentation in medical research - University Paris 7, France. 2006 - Degree of Ecole Pratique des Hautes Etudes (EPHE) - Paris, France. \- Degree Inter University (DIU) of Cytometry in Research - EPHE - Paris, France. 2004 - Degree of Technician in Biomedical Analysis (DETAB), Catholic University, Lyon, France. **POSITION** 2017-actual - Researcher (CRCN - CNRS) - Cancer Research Center of Toulouse (CRCT), UMR1037, France. 2011-2017 - PostDoc - Supervisor: T, Hoang - IRIC - University of Montreal, Canada. 2006-2010 - Ph.D - Supervisor: F, Pflumio - CEA, INSERM U967 - Fontenay-Aux-Roses, France. 2004-2006 - EPHE student - Supervisor: X, Ronot - UMR CNRS 5525 - La Tronche, France. **GRANTS** 2018 - Ligue Contre le Cancer (Fundamental and translational research program) - 25 000 €. \- ARC foundation (Consolidator grant) - 50 000 €. \- ANR (Agence Nationale de la Recherche) young investigator (Program JCJC) - 253 800 €. **FELLOWSHIPS** 2016 - Postdoctoral fellowship (2 years): ARC Foundation, Paris, France (declined). \- Postdoctoral fellowship (2 years): Ligue Nationale Contre le Cancer, Paris, France. 2013 - Postdoctoral fellowship (2 years): Fond de Recherche en Santé du Québec, Canada. \- Postdoctoral fellowship (2 years): Cole Foundation, Montreal, Canada. 2011 - Post-doctoral fellowship (2 years): Cole Foundation, Montreal, Canada. 2010 - Doctoral fellowship (1 year): Société Française d’Hématologie, Paris, France.¬ 2007 - Doctoral fellowship (3 years): Ligue National Contre le Cancer, Paris, France. **AWARDS AND DISTINCTIONS** 2018 - Prize young investigator. FONROGA – Roland Garrigou Foundation. 2017 - First Prize for poster presentation. T-ALL workshop, Leuven, Belgium. 2016 - Abstract Achievement Award. American Society of Hematology (ASH), San Diego, USA. 2015 - First prize of oral presentation. IRIC 6th scientific day, IRIC, Montreal, Canada. \- First prize of oral presentation. New Investigator Postdoctoral Fellow “Eugene Cronkite” Award, ISEH meeting, Kyoto, Japan. Interview in “Meet a New Investigator Award Winner”. Experimental Hematology / ISEH / Connections Newsletter. http://iseh.site-ym.com/blogpost/611221/Member-Profile \- Travel award from Canadian Cancer Society for the 2015 ISEH meeting (Kyoto, Japan). \- First prize for poster presentation. Cole Fellowship Exhibition. Montreal, Canada. 2014 - First prize for poster presentation. Cole Fellowship Exhibition. Montreal, Canada. 2012 - Abstract Achievement Award. American Society of Hematology (ASH), Atlanta, USA. - First prize for poster presentation. Cole Fellowship Exhibition. Montreal, Canada. **PEOPLE MANAGEMENT** 2017-actual - Supervision of 2 PhD students - Cancer Research Center of Toulouse (CRCT), UMR1037, France. (1 PhD fellow and 1 PhD supported by ANR grant – Doctoral School BSB – UPS – Toulouse) \- Supervision of 3 Master students - Cancer Research Center of Toulouse (CRCT), UMR1037, France. 2011-2016 - Supervision of 9 Master students - IRIC - University of Montreal, Canada. **TEACHING ACTIVITIES** 2019-2020 - Theorical classe in Faculty of Pharmacology - UE Differentiation and Oncogenesis (3 hours/year) Paul Sabatier University, Toulouse. 2014-2016 - Theorical classes in Cancer Pharmacology to Master students (3 hours/year) University of Montreal, Canada. 2011-2016 - Practical works in flow cytometry to Master students (10 hours/year) IRIC - University of Montreal, Canada. 2009 - Theorical classe to Ph.D students – Doctoral School B2T, Saint Louis Hospital, Paris, France. **PRESENTATIONS AND CONFERENCES** *Invited conferences* 2015-2020 - 7 conferences as invited speaker. *Selected talks* 2005-2018 - 19 short talks (including 8 in international meetings). *Poster presentations* 2005-2018 - 14 poster presentations (including 6 in international meetings). **MANUSCRIPT AND GRANT EVALUATIONS** 2012-actual - Reviewer or co-reviewer of manuscripts submitted for publication in Blood, Molecular Biology Reports, Experimental Cell Research, Molecular Cell Biology, Stem Cell, World Journal of Gastroenterology, Hematologica. 2018 - Member of a scientific review panel for the funding competition “Fonds d’innovation thérapeutiques”- CHU - Sainte Justine, Montreal, Canada. \- Reviewer of a grant applied to Research Foundation Flanders-FWO. 2014 - Co-reviewer of a grant applied to Canadian Cancer Society Research Institute. **PUBLICATIONS** 1- Gerby B and Hoang T. A targetable cue in T-cell malignancy. Blood commentary. 2020, in press. (Commentary of the article from De Smedt R et al., Targeting cytokine and therapy-induced PIM1 activation in T-cell acute lymphoblastic leukemia and lymphoma. Blood, 2020, in press). 2- Jamrog L, Chemin G, Fregona V, Oudinet C, Rouquie N, Prade N, Lagarde S, Cresson C1, Hebrard S, Nguyen Huu N, Bousquet M, Quelen C, Brousset P, Mancini S, Delabesse E, Khamlichi A.A, Gerby B\* and Broccardo C\*. PAX5-ELN oncoprotein promotes multistep B-cell acute lymphoblastic leukemia in mice. Proc Natl Acad Sci USA. 2018 Oct 9;115(41):10357-62. (Impact factor : 9.5). \*equal contribution and co-corresponding authors. 3- Cresson C, Peron S, Jamrog L, Rouquie N, Prade N, Dubois M, Hebrard S, Lagarde S, Gerby B, Mancini S, Cogné M, Delabesse E, Delpy L and Broccardo C. PAX5A and PAX5B isoforms are both efficient to drive B-cell differentiation. Oncotarget. 2018 Aug 28;9(67):32841-54 (Impact factor : 5.17). 4- Gerby B, Veiga D.F, Krosl J, Nourreddine S, Ouellette J, Haman A, Lavoie G, Fares I, Tremblay M, Litalien V, Ottoni E, Kosic M, Geoffrion D, Ryan J, Maddox P, Chagraoui J, Marinier A, Hébert J, Sauvageau G, Kwok B.H, Roux PP, and Hoang T. High-throughput screening in niche-based assay identifies compounds to target pre-leukemic stem cells. J Clin Invest. 2016 Dec 1;126(12):4569-84 (Impact factor : 12.57). 5- Gerby B, Tremblay C.S, Tremblay M, Veiga D.F, Rojas-Sutterlin S, Ryan J, Maddox P.S, Hébert J, Sauvageau G, Lécuyer E and Hoang T. The SCL, LMO1 and Notch1 oncogenes reprogram T-lymphocyte progenitors into self-renewing cells. PloS Genetics. 2014 Dec 18;10(12). (Impact factor : 8.52). See perspective: Goossens S and Van Vlierberghe P. Controlling Pre-leukemic Thymocyte Self-Renewal. PlosGenetics, 2014, Dec 18;10. 6- Uzan B, Poglio S, Gerby B, Wu CL, Armstrong F, Calvo J, Cahu X, Deswarte C, Dumont F, Leblanc T, Baruchel A, Balerini P, Baleydier F, Porteu F and Pflumio F. The pro-inflammatory IL-18 cytokine produced by bone marrow derived stromal cells participates into T acute leukemia progression. EMBO Molecular Medicine. 2014, Apr 28;6(6):821-34. (Impact factor: 8.8). 7- Lacombe J, Krosl G\*, Tremblay M\*, Gerby B\*, Martin R, Aplan P, Lemieux S, Hoang T. Genetic interaction between Kit and Scl. Blood. 2013 Aug 15;122(7):1150-61. (Impact factor: 9.90). \*equal contribution. 8- Gerby B and Hoang T. Modelling acute leukemias in mice: clonal evolution and the emergence of leukemic stem cells. BMC Proceedings, 2013 (Keynote Lecture Presentation), 7(Suppl 2):K1. 9- Thiollier C, Lopez CK, Gerby B, Ignacimouttou C, Poglio S, Duffourd S, Guégan J, Rivera-Munoz P, Bluteau O, Mabialah V, Diop M, Wen Q, Petit A, Bauchet AL, Bornhauser B, Gautheret D, Lecluse Y, Landman-Parker J, Radford I, Vainchenker W, Dastugue N, De Botton S, Dessen P, Bourquin JP, Crispino JD, Ballerini P, Bernard OA, Pflumio F and Mercher T. Xenograft models of pediatric acute megakaryoblastic leukemia contribute to identification of novel recurrent fusion genes. J Exp Med. 2012 Oct 22;209(11):2017-31. (Impact factor: 13.85). 10- Wen Q, Goldenson B, Silver SJ, Schenone M, Dancik V, Huang Z, Wang LZ, Lewis TA, An WF, Li X, Bray MA, Thiollier C, Diebold L, Gilles L, Vokes MS, Moore CB, Bliss-Moreau M, Verplank L, Tolliday NJ, Mishra R, Vemula S, Shi J, Wei L, Kapur R, Lopez CK, Gerby B, Ballerini P, Pflumio F, Gilliland DG, Goldberg L, Birger Y, Izraeli S, Gamis AS, Smith FO, Woods WG, Taub J, Scherer CA, Bradner JE, Goh BC, Mercher T, Carpenter AE, Gould RJ, Clemons PA, Carr SA, Root DE, Schreiber SL, Stern AM, Crispino JD. Identification of Regulators of Polyploidization Presents Therapeutic Targets for Treatment of AMKL. Cell. 2012 Aug 3;150(3):575-89. (Impact factor : 32.40). 11- Gerby B, Clappier E, Armstrong F, Deswarte C, Calvo J, Poglio S, Soulier J, Boissel N, Leblanc T, Baruchel A, Landman-Parker J, Roméo PH, Ballerini P, Pflumio F. Expression of CD34 and CD7 on human T-cell acute lymphoblastic leukemia discriminates functionally heterogeneous cell populations. Leukemia. 2011 Aug 25(8):1249-58. (Impact factor : 9.56). 12- Clappier E, Gerby B, Delord M, Touzri M, Hernandez L, Ballerini P, Sigaux F, Baruchel A, Pflumio F, Soulier J. Clonal selection in xenografted human T-cell acute lymphoblastic leukemia recapitulates gain of malignancy at relapse. J Exp Med. 2011 Apr 11;208(4):653-61. (Impact factor : 13.85). 13- Pflumio F, Kusy S, Gerby B, Roméo PH. How a suppressor of tumor gets hooked of the leukaemic proliferation in man. Med Sci (Paris). 2011 Feb;27(2):142-3. Epub 2011 Mar 8. (Impact factor : 0.52). 14- Kusy S, Gerby B, Goardon N, Gault N, Ferri F, Gérard D, Armstrong F, Ballerini P, Pflumio F, Roméo PH. NKX3.1 is a direct TAL1 target gene that mediates proliferation of TAL1-expressing human T-ALL. J Exp Med, 2010 Sep 27;207(10):2141-56. (Impact factor : 14.78). 15- Barattin R, Gerby B, Bourges K, Hardy G, Olivares J, Boutonnat J, Arnoult C, Du Moulinet D’Hardemare A and Ronot X. Iodination increases the activity of verapamil derivates in reversing PGP multidrug resistance. Anticancer Research, 2010 Jul 30(7):2553-9. (Impact factor : 1.66). 16- Gerby B, Armstrong F, Brunet de la Grange P, Medyouf H, Calvo J, Verhoeyen Els, Cosset FL, Bernstein I, Amselem S, Boissel N, Dombret H, Leblanc T, Baruchel A, Landman-Parker J, Ballerini P et Pflumio F. Optimized gene transfer into human primary T cell acute leukemia conserving NOD-SCID /leukemia-Initiating-Cell activity. Leukemia, 2010 Mar 24(3):646-9. (Impact factor : 8.97). 17- Gerby B, Armstrong F, Brunet de la Grange P, Calvo J, Balérini P, Pflumio F. Mise en évidence des cellules souches leucémiques dans les LAL-T humaines et étude de l’implication des voies NOTCH, TAL-1 et ERK/MAPK dans la leucémogénèse T humaine. Annales de pathologie, 2008 Nov;28 Spec No 1(1):S28-9. (Impact factor : 0.47). 18- Armstrong F, Brunet de la Grange P, Gerby B, Rouyez MC, Calvo J, Fontenay M, Boissel N, Dombret H, Baruchel A, Landman-Parker J, Romeo PH, Ballerini P, Pflumio F. NOTCH is a key regulator of human T-cell acute leukaemia initiating cell activity. Blood, 2009 Feb 19 (113) :1730-1740. (Impact factor : 10.56). 19- Gerby B, Boumendjel A, Champelovier P, Bringuier PP, Fortuné A, Colle PE, Ronot X, Boutonnat J. 2-Arylidenedihydroindole-3-ones : Design, synthesis and biological activity on Bladder Carcinoma cell lines. Bioorganic and Medicinal Chemistry, 2007 Jan 1;17(1):208-13. (Impact factor : 3.08). 20- Boumendjel A, Nicolle E, Moraux T, Gerby B, Blanc M, Ronot X, and Boutonnat J. Piperazinobenzopyranones and Phenalkylaminobenzopyranones: Potent Inhibitors of Breast Cancer Resistance Protein (ABCG2). Journal of Medicinal Chemistry, 2005 Nov 17;48(23):7275-81. (Impact factor : 5.20).